Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Caribou Biosciences, Inc.

Clinical trials sponsored by Caribou Biosciences, Inc., explained in plain language.

Caribou Biosciences, Inc. CRBU NASDAQ

A clinical-stage biopharmaceutical company developing CRISPR-based cell therapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 2

Gene-Edited immune cells take on Hard-to-Treat blood cancer

Disease control Recruiting now

This early-stage study tests a new treatment called CB-011 for people with multiple myeloma that has returned or stopped responding to other therapies. CB-011 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The study aims to find the saf…

Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC